Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07303907 · ClinicalTrials.gov registry record · Phase 2
A Phase 2A Trial of MM402 for Autism Spectrum Disorder
A Phase 2 study of Autism Spectrum Disorder and ASD, sponsored by Definium Therapeutics US.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07303907 is a Phase 2 study of Autism Spectrum Disorder and ASD that is actively recruiting participants, run by Definium Therapeutics US. The registered enrollment target is 20 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07303907, a Phase 2 study of Autism Spectrum Disorder and ASD, is actively recruiting participants, sponsored by Definium Therapeutics US.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 2A Trial of MM402 Open-Label Study in Adults with Autism Spectrum Disorder
Conditions Studied
Interventions
- DRUG MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Study Locations (1)
New York
- Spectrum Neuroscience and Treatment Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07303907
The ClinicalTrials.gov registry entry for NCT07303907 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (85% lower). The listed sponsor is Definium Therapeutics US, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) is the first listed.
NCT07303907 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07303907 about?
NCT07303907 is a clinical study titled "A Phase 2A Trial of MM402 for Autism Spectrum Disorder". A Phase 2A Trial of MM402 Open-Label Study in Adults with Autism Spectrum Disorder
What is the current status of trial NCT07303907?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-12-03. Estimated completion is 2027-08.
What conditions does trial NCT07303907 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, ASD.
What interventions are being tested in trial NCT07303907?
The interventions under investigation include: MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) (DRUG).
Who is sponsoring clinical trial NCT07303907?
This trial is sponsored by Definium Therapeutics US, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07303907 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
RECRUITING · Phase 2
-
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
RECRUITING · Phase 2
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.